


Daphnetin

Cat. No.:	HY-N0281												
CAS No.:	486-35-1												
Molecular Formula:	C ₉ H ₆ O ₄												
Molecular Weight:	178.14												
Target:	EGFR; PKA; PKC; Autophagy; Parasite; Apoptosis; AMPK; Akt; mTOR; Reactive Oxygen Species; Caspase; Bcl-2 Family; PARP												
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; TGF-beta/Smad; Epigenetics; Autophagy; Anti-infection; Apoptosis; PI3K/Akt/mTOR; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Cell Cycle/DNA Damage												
Storage:	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>6 months</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 month</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	6 months		-20°C	1 month
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	6 months											
	-20°C	1 month											



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (280.68 mM; Need ultrasonic)
 H₂O : 1 mg/mL (5.61 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	5.6136 mL	28.0678 mL	56.1356 mL
	5 mM	1.1227 mL	5.6136 mL	11.2271 mL
	10 mM	0.5614 mL	2.8068 mL	5.6136 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 50% PEG300 >> 50% saline
 Solubility: 25 mg/mL (140.34 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (14.03 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (14.03 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (14.03 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative can be found in plants of the Genus Daphne, is a potent, oral active protein kinase inhibitor, with IC ₅₀ s of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively. Daphnetin triggers ROS-induced cell apoptosis and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway. Daphnetin has anti-inflammation activity and inhibits TNF-α, IL-1β, ROS, and MDA production. Daphnetin has schizontocidal activity against malaria parasites. Daphnetin can be used for rheumatoid arthritis, cancer and anti-malarian research ^{[1][2][3][4]} .																																			
IC₅₀ & Target	EGFR 7.67 μM (IC ₅₀)	Plasmodium	PKA 9.33 μM (IC ₅₀)	PKC 25.01 μM (IC ₅₀)																																
In Vitro	<p>Daphnetin (7,8-dihydroxycoumarin) (0-40 μg/mL; 24-48 hours) inhibits the proliferation of ovarian cancer cells^[1].</p> <p>Daphnetin (7,8-dihydroxycoumarin) (0-40 μg/mL; 24 hours; A2780 cells) induces apoptosis and increases ROS production in a dose-dependent manner^[1].</p> <p>Daphnetin (7,8-dihydroxycoumarin) (0-40 μg/mL; 24 hours; A2780 cells) induces autophagy through modulation of the AMPK/Akt/mTOR pathway^[1].</p> <p>Daphnetin (7,8-dihydroxycoumarin) (1-10 μM; plasmodium falciparum) exhibits schizontocidal activity in a dose-dependent manner^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1" data-bbox="363 800 1516 1031"> <tr> <td>Cell Line:</td> <td>IOSE8C, A2780, SKOV3 and OVCAR8 cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 5, 10, 20 and 40 μg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h and 48 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited growth in ovarian cancer cells but not in normal cells.</td> </tr> </table> <p>Apoptosis Analysis^[1]</p> <table border="1" data-bbox="363 1104 1516 1335"> <tr> <td>Cell Line:</td> <td>A2780 and SKOV3 cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 10, 20 and 40 μg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Increased apoptosis in a dose-dependent manner in A2780 and SKOV3 cells.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1" data-bbox="363 1409 1516 1671"> <tr> <td>Cell Line:</td> <td>A2780 and SKOV3 cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 10, 20 and 40 μg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Increased proapoptotic protein (Caspase 3, Bax, and PARP) expression but decreased antiapoptotic protein (Bcl2) expression.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1" data-bbox="363 1745 1516 1976"> <tr> <td>Cell Line:</td> <td>A2780 cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 10, 20 and 40 μg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Increased LC3 II and p62 expression in a dose-dependent manner and reduced the</td> </tr> </table>				Cell Line:	IOSE8C, A2780, SKOV3 and OVCAR8 cells	Concentration:	0, 5, 10, 20 and 40 μg/mL	Incubation Time:	24 h and 48 hours	Result:	Inhibited growth in ovarian cancer cells but not in normal cells.	Cell Line:	A2780 and SKOV3 cells	Concentration:	0, 10, 20 and 40 μg/mL	Incubation Time:	24 hours	Result:	Increased apoptosis in a dose-dependent manner in A2780 and SKOV3 cells.	Cell Line:	A2780 and SKOV3 cells	Concentration:	0, 10, 20 and 40 μg/mL	Incubation Time:	24 hours	Result:	Increased proapoptotic protein (Caspase 3, Bax, and PARP) expression but decreased antiapoptotic protein (Bcl2) expression.	Cell Line:	A2780 cells	Concentration:	0, 10, 20 and 40 μg/mL	Incubation Time:	24 hours	Result:	Increased LC3 II and p62 expression in a dose-dependent manner and reduced the
Cell Line:	IOSE8C, A2780, SKOV3 and OVCAR8 cells																																			
Concentration:	0, 5, 10, 20 and 40 μg/mL																																			
Incubation Time:	24 h and 48 hours																																			
Result:	Inhibited growth in ovarian cancer cells but not in normal cells.																																			
Cell Line:	A2780 and SKOV3 cells																																			
Concentration:	0, 10, 20 and 40 μg/mL																																			
Incubation Time:	24 hours																																			
Result:	Increased apoptosis in a dose-dependent manner in A2780 and SKOV3 cells.																																			
Cell Line:	A2780 and SKOV3 cells																																			
Concentration:	0, 10, 20 and 40 μg/mL																																			
Incubation Time:	24 hours																																			
Result:	Increased proapoptotic protein (Caspase 3, Bax, and PARP) expression but decreased antiapoptotic protein (Bcl2) expression.																																			
Cell Line:	A2780 cells																																			
Concentration:	0, 10, 20 and 40 μg/mL																																			
Incubation Time:	24 hours																																			
Result:	Increased LC3 II and p62 expression in a dose-dependent manner and reduced the																																			

expression levels of p-Akt, p-mTOR, but increased the expression level of p-AMPK.

In Vivo

Daphnetin (7,8-dihydroxycoumarin) (30 mg/kg; i.p.; daily; for 12 days; BALB/c nude mice) has antitumour activities in a xenograft animal model^[1].

Daphnetin (7,8-dihydroxycoumarin) (2.5-10 mg/kg; i.p.; daily; for three days; C57BL/6 mice) inhibits cisplatin-induced inflammation, decreases TNF- α , IL-1 β , ROS and MDA production in a dose-dependent manner in kidney tissues. Daphnetin inhibits cisplatin-induced NF- κ B activation and up-regulated Nrf2 and HO-1^[2].

Daphnetin (7,8-dihydroxycoumarin) (10-100 mg/kg; i.g. and i.p.; every four days, for 30 days; male Kunming outbred strain mice) displays certain schizontocidal activity in vivo^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c nude mice ^[1]
---------------	---------------------------------

Dosage:	30 mg/kg
---------	----------

Administration:	Intraperitoneal injection; Daily; for 12 days
-----------------	---

Result:	Decreased tumor volume and weight in a xenograft animal model.
---------	--

Animal Model:	Male Kunming outbred strain mice ^[3]
---------------	---

Dosage:	10, 50 or 100 mg/kg
---------	---------------------

Administration:	Oral gavage and intraperitoneal injection; every four days, for 30 days
-----------------	---

Result:	Reduced the number of parasites in mice.
---------	--

CUSTOMER VALIDATION

- Am J Pathol. 2022 Sep 20;S0002-9440(22)00281-4.
- Pharmacology. 2021 Apr 26;1-15.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Fan X, et, al. Daphnetin triggers ROS-induced cell death and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway in ovarian cancer. *Phytomedicine*. 2021 Feb;82:153465.

[2]. Zhang L, et, al. Daphnetin protects against cisplatin-induced nephrotoxicity by inhibiting inflammatory and oxidative response. *Int Immunopharmacol*. 2018 Dec;65:402-407.

[3]. Wang QM, et, al. The schizontocidal activity of daphnetin against malaria parasites in vitro and in vivo. *Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi*. 2000;18(4):204-6.

[4]. Yang EB, Zhao YN, Zhang K, Mack P. Daphnetin, one of coumarin derivatives, is a protein kinase inhibitor. *Biochem Biophys Res Commun*. 1999 Jul 14;260(3):682-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA